Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood thinners after birth: could they save lives of new moms at moderate risk?

NCT ID NCT06845423

Prevention Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving blood thinners (LMWH) for 6 weeks after childbirth can prevent dangerous blood clots in women who have a moderate risk. About 2,400 women will be randomly assigned to receive either the blood thinner or standard care without it. The goal is to see if this approach reduces the chance of clots, which are a leading cause of death in new mothers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 2,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women at intermediate risk of VTE during post-partum= with a 3% or more risk of VTE based on a validated prediction model\* or International guidelines (ACCP 2012). * Age over 18 years * Delivery between 6 hours and \< 36 hours * Written informed consent * Definition: Intermediate risk is defined as ≥ 3%, based on risk prediction model developed by Sultan et al taking in account: smoking, varicose veins, obesity, comorbidities, diabetes, pre-eclampsia, post-partum hemorrhage, postpartum infection, emergency or elective section or following ACCP guidelines: one major risk factor or two minor risk factors. Exclusion Criteria: * Previous personal history of VTE * LMWH started during antenatal period * Need for anticoagulation at curative dose * Contraindication to LMWH (previous heparin induced thrombopenia, hemostatic impairment, known severe renal insufficiency) * Women who received more than two doses of LMWH since delivery * Unable or refusal to give informed consent * Aspirin at a daily dose 100 mg or dual antiplatelet therapy * Previous inclusion in Mum-VTE study * Concomitant participation in another therapeutic study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post partum women are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

puerperal disorder venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post partum women Venous thromboembolism (VTE)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    18 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH de Pau

    RECRUITING

    Pau, 64000, France

  • CH départemental de Vendée

    NOT_YET_RECRUITING

    La Roche-sur-Yon, 85000, France

  • CHRU de Nancy

    NOT_YET_RECRUITING

    Nancy, 54000, France

  • CHU d'Amiens Picardie

    NOT_YET_RECRUITING

    Amiens, 80054, France

  • CHU de Bordeaux, Groupe Pellegrin, Centre Aliénor d'Aquitaine

    NOT_YET_RECRUITING

    Bordeaux, 33000, France

  • CHU de Brest

    RECRUITING

    Brest, 29200, France

  • CHU de Clermont Ferrand Site Estaing

    NOT_YET_RECRUITING

    Clermont-Ferrand, 63000, France

  • CHU de Nantes

    NOT_YET_RECRUITING

    Nantes, 44000, France

  • CHU de Rennes

    NOT_YET_RECRUITING

    Rennes, 35203, France

  • CHU de St Etienne - Hôpital Nord

    NOT_YET_RECRUITING

    Saint-Priest-en-Jarez, 42270, France

  • Centre Hospitalier de Cornouaille Quimper Concarneau

    NOT_YET_RECRUITING

    Quimper, 29000, France

  • Centre Hospitalier de Périgueux

    NOT_YET_RECRUITING

    Périgueux, 24019, France

  • Centre Hospitalier des Pays de Morlaix

    NOT_YET_RECRUITING

    Morlaix, 29600, France

  • Groupe Hospitalier Paris Saint Joseph

    NOT_YET_RECRUITING

    Paris, 75014, France

  • Hôpital Bicêtre, AP-HP

    NOT_YET_RECRUITING

    Le Kremlin-Bicêtre, 94720, France

  • Hôpital Béclère, AP-HP

    NOT_YET_RECRUITING

    Clamart, 92140, France

  • Hôpital Lariboisière, AP-HP

    NOT_YET_RECRUITING

    Paris, 75010, France

  • Hôpital Nord Marseille, AP-HM

    NOT_YET_RECRUITING

    Marseille, 13015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.